Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Lung Function Decline After Antifibrotic Therapy Predicts Survival in IPF, Study Shows
- Inhaled Nintedanib May Reduce Side Effects of Oral Formulation, Rat Study Shows
- Ofev Effective in IPF Patients With Poor Lung Function, Real-world Study Finds
- Years of Ofev Use in Clinic Raise No New Safety Concerns, Study Finds
- Similar Satisfaction Among IPF Patients Treated With Ofev or Esbriet, Study Finds
- 1st Participant Enrolled in Phase 3 Trial Testing Ofev in Children With Fibrosing ILDs
- Ofev Helps to Preserve Lung Function in Progressive ILD Patients, Trial Data Show
IPF News:
- Procalcitonin Blood Levels May Help Detect Lung Cancer in IPF Patients, Study Suggests
- Biognosys, Boehringer Ingelheim Partner for Protein Studies of IPF
- World’s First Single-cell Sequencing Atlas Available for Drug Discovery in IPF
- IPF Hospitalizations, Mortality Rate Seen to Drop in US from 2006-16
- Algernon’s NP-120 Surpasses Merck’s MK-7264 in Reducing Cough Frequency in Animal Model of Acute Cough, Study Shows
- Algernon Plans Launch of First Phase 2 Trial on Repurposed IPF or IBD Compound by Mid-2020
- FDA Grants Orphan Drug Status to Nitric Oxide as Potential IPF Treatment
Esbriet News:
- Trial to Test Higher Dose of Inhaled Pirfenidone in All Participants
- Esbriet Treatment Seems Safe in IPF Patients With Lung Cancer, Study Reports
- Lung Function Decline After Antifibrotic Therapy Predicts Survival in IPF, Study Shows
- Similar Satisfaction Among IPF Patients Treated With Ofev or Esbriet, Study Finds
- Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports
- Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF
- Potential IPF Treatment Limits Weight Loss, Lung Scarring in Mouse Model
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- UK Trial Recruiting IPF Patients to Test Nalbuphine Extended Release Tablets for Chronic Cough
- ART-123 Doesn’t Prolong Life in IPF Acute Exacerbations, Study Says
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
FDA News:
- Ofev Approved in US and Canada for Progressive Fibrosing ILDs
- FDA Names AMP945, Potential IPF Treatment, an Orphan Drug
- Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
- FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar
- NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC
- FDA Grants Orphan Drug Status to Nitric Oxide as Potential IPF Treatment
- EmphyCorp’s N115 Completes Phase 3 Trial for FDA Marketing Application in PF Patients